Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Medicine
Volume 2013 (2013), Article ID 348628, 4 pages
http://dx.doi.org/10.1155/2013/348628
Case Report

Multifocal Buruli Ulcer Associated with Secondary Infection in HIV Positive Patient

Department of Dermatology and Infectiology, School of Medicine, Felix Houphouét Boigny University of Abidjan, BP 01 V166 Abidjan 01, Cote d’Ivoire

Received 20 June 2013; Revised 6 December 2013; Accepted 12 December 2013

Academic Editor: T. Ottenhoff

Copyright © 2013 Kassi Komenan et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. A. Chauty, M.-F. Ardant, L. Marsollier et al., “Oral treatment for Mycobacterium ulcerans infection: results from a pilot study in Benin,” Clinical Infectious Diseases, vol. 52, no. 1, pp. 94–96, 2011. View at Publisher · View at Google Scholar · View at Scopus
  2. W. A. Nienhuis, Y. Stienstra, W. A. Thompson et al., “Antimicrobial treatment for early, limited Mycobacterium ulcerans infection: a randomised controlled trial,” The Lancet, vol. 375, no. 9715, pp. 664–672, 2010. View at Publisher · View at Google Scholar · View at Scopus
  3. A. Toll, F. Gallardo, M. Ferran et al., “Aggressive multifocal Buruli ulcer with associated osteomyelitis in an HIV-positive patient,” Clinical and Experimental Dermatology, vol. 30, no. 6, pp. 649–651, 2005. View at Publisher · View at Google Scholar · View at Scopus
  4. D. P. O'Brien, M. E. Robson, P. P. Callan, and A. H. McDonald, ““Paradoxical” immune-mediated reactions to Mycobacterium ulcerans during antibiotic treatment: a result of treatment success, not failure,” Medical Journal of Australia, vol. 191, no. 10, pp. 564–566, 2009. View at Google Scholar · View at Scopus
  5. A. Singal, S. Mehta, and D. Pandhi, “Immune reconstitution inflammatory syndrome in an HIV seropositive leprosy patient,” Leprosy Review, vol. 77, no. 1, pp. 76–80, 2006. View at Google Scholar · View at Scopus
  6. N. F. Crum-Cianflone, “Immune reconstitution inflammatory syndromes: what's new?” AIDS Reader, vol. 16, no. 4, pp. 199–217, 2006. View at Google Scholar · View at Scopus
  7. G. E. Sopoh, A. D. Dossou, L. V. Brun et al., “Case report: severe multifocal form of buruli ulcer after streptomycin and rifampin treatment: comments on possible dissemination mechanisms,” American Journal of Tropical Medicine and Hygiene, vol. 83, no. 2, pp. 307–313, 2010. View at Publisher · View at Google Scholar · View at Scopus
  8. H. H. Hirsch, G. Kaufmann, P. Sendi, and M. Battegay, “Immune reconstitution in HIV-infected patients,” Clinical Infectious Diseases, vol. 38, no. 8, pp. 1159–1166, 2004. View at Publisher · View at Google Scholar · View at Scopus
  9. S. F. Stone, P. Price, M.-L. Tay-Kearney, and M. A. French, “Cytomegalovirus (CMV) retinitis immune restoration disease occurs during highly active antiretroviral therapy-induced restoration of CMV-specific immune responses within a predominant Th2 cytokine environment,” Journal of Infectious Diseases, vol. 185, no. 12, pp. 1813–1817, 2002. View at Publisher · View at Google Scholar · View at Scopus
  10. R. C. Johnson, D. Ifebe, A. Hans-Moevi et al., “Disseminated Mycobacterium ulcerans disease in an HIV-positive patient: a case study [9],” AIDS, vol. 16, no. 12, pp. 1704–1705, 2002. View at Publisher · View at Google Scholar · View at Scopus
  11. WHO, “WHO 7.4. monitoring and substitute for ARV drug toxicities,” Consolidate ARV Guidelines, 2013, www.who.int/hiv/pub/guidelines/arv2013/art/drugstoxicities/en/index 5.html. View at Google Scholar